Fig. 4

Kaplan-Meier survival plots for disease-specific survival and disease-free survival based on low expression of GSTM3 versus high expression of GSTM3 for ESCC patients. a Disease-specific survival for ESCC patients in the mRNA cohort. No significant difference in DSS between low-expression and high-expression groups, log-rank test, p = 0.132. b Disease-specific survival for ESCC patients in the protein cohort. No significant difference in DSS between low-expression and high-expression groups, log-rank test, p = 0.070. c Disease-free survival for ESCC patients in the mRNA cohort. Patients with low GSTM3 expression had a poorer disease-free survival than those with high GSTM3 expression, log-rank test, p = 0.016. d Disease-free survival for ESCC patients in the protein cohort. Patients with low GSTM3 expression exhibited poorer disease-free survival compared with those with high GSTM3 expression, log-rank test, p = 0.006